New hope for transplant patients: daily IL-2 shots tame stubborn immune attack
NCT ID NCT01366092
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 26 times
Summary
This study tested whether a daily low-dose injection of IL-2 can help control chronic graft-versus-host disease (cGVHD) in 35 people who had not improved with steroids. cGVHD is a condition where donor immune cells attack the recipient's body after a stem cell or bone marrow transplant. The goal was to see if IL-2 could calm this immune response and allow patients to reduce their steroid use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02214, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.